Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 4305 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Glucagon-like peptide-1 analogues: An overview

Gupta Vishal

Year : 2013| Volume: 17| Issue : 3 | Page no: 413-421

   This article has been cited by
1 Polymeric microparticle systems for modified release of glucagon-like-peptide-1 receptor agonists
Luis Peña Icart,Fernando Gomes Souza Jr,Luís Maurício T. R. Lima
Journal of Microencapsulation. 2021; : 1
[Pubmed]  [Google Scholar] [DOI]
2 The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion and mood: a review
Eva Guerrero Hreins,Anthony P. Goldstone,Robyn M. Brown,Priya Sumithran
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2021; : 110303
[Pubmed]  [Google Scholar] [DOI]
3 Liraglutide Protects Nucleus Pulposus Cells Against High-Glucose Induced Apoptosis by Activating PI3K/Akt/ mTOR/Caspase-3 and PI3K/Akt/GSK3ß/Caspase-3 Signaling Pathways
Mingyan Yao,Jing Zhang,Zhihong Li,Xiaoliang Bai,Jinhui Ma,Yukun Li
Frontiers in Medicine. 2021; 8
[Pubmed]  [Google Scholar] [DOI]
4 Engineering of smart nanoconstructs for delivery of glucagon-like peptide-1 analogs
Noura G. Eissa,Mahmoud Elsabahy,Ayat Allam
International Journal of Pharmaceutics. 2021; 597: 120317
[Pubmed]  [Google Scholar] [DOI]
5 DBPR108, a novel dipeptidyl peptidase-4 inhibitor with antihyperglycemic activity
Kai-Chia Yeh,Teng-Kuang Yeh,Chung-Yu Huang,Chih-Bo Hu,Min-Hsien Wang,Yu-Wen Huang,Ling-Hui Chou,Hsuan-Hui Ho,Jen-Shin Song,Tsu Hsu,Weir-Torn Jiaang,Yu-Sheng Chao,Chiung-Tong Chen
Life Sciences. 2021; 278: 119574
[Pubmed]  [Google Scholar] [DOI]
6 Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice
Hyo Shin Yoon,Chung Hwan Cho,Myeong Sik Yun,Sung Jae Jang,Hyun Ju You,Jun-hyeong Kim,Dohyun Han,Kwang Hyun Cha,Sung Hyun Moon,Kiuk Lee,Yeon-Ji Kim,Sung-Joon Lee,Tae-Wook Nam,GwangPyo Ko
Nature Microbiology. 2021; 6(5): 563
[Pubmed]  [Google Scholar] [DOI]
7 The impact of different modes of exercise training on GLP-1: a systematic review and meta-analysis research
Reihaneh Nejati,Nahid Bijeh,Morteza Motahari Rad,Seyyed Reza Attarzadeh Hosseini
International Journal of Diabetes in Developing Countries. 2021;
[Pubmed]  [Google Scholar] [DOI]
8 Discovery through Machine Learning and Preclinical Validation of Novel Anti-Diabetic Peptides
Rory Casey,Alessandro Adelfio,Martin Connolly,Audrey Wall,Ian Holyer,Nora Khaldi
Biomedicines. 2021; 9(3): 276
[Pubmed]  [Google Scholar] [DOI]
9 Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
Takayuki Yamada,Mako Wakabayashi,Abhinav Bhalla,Nitin Chopra,Hirotaka Miyashita,Takahisa Mikami,Hiroki Ueyama,Tomohiro Fujisaki,Yusuke Saigusa,Takahiro Yamaji,Kengo Azushima,Shingo Urate,Toru Suzuki,Eriko Abe,Hiromichi Wakui,Kouichi Tamura
Cardiovascular Diabetology. 2021; 20(1)
[Pubmed]  [Google Scholar] [DOI]
10 Assessing the Continuation of Glucagon-Like Peptide-1 Receptor Agonists When Weight and HBA1C Are Not Reduced
Rona Zhou,Karsten Duncan,Julio Lopez,Kjersti Rich,Arthur Swislocki
Metabolic Syndrome and Related Disorders. 2020;
[Pubmed]  [Google Scholar] [DOI]
11 Recent advances in understanding the role of glucagon-like peptide 1
Josh Reed,Stephen Bain,Venkateswarlu Kanamarlapudi
F1000Research. 2020; 9: 239
[Pubmed]  [Google Scholar] [DOI]
12 Type II diabetes mellitus: a review on recent drug based therapeutics
Santwana Padhi,Amit Kumar Nayak,Anindita Behera
Biomedicine & Pharmacotherapy. 2020; 131: 110708
[Pubmed]  [Google Scholar] [DOI]
13 Effect of Glucagon-like peptide-1 agonist (liriglutide) on weight and glycemic control among adults with type 2 diabetes mellitus attending primary care center at security forces hospital in Riyadh, Saudi Arabia
NaifahK Alanazi,MedhatA Ghoraba
Journal of Family Medicine and Primary Care. 2020; 9(8): 3933
[Pubmed]  [Google Scholar] [DOI]
14 Apigenin modulates hippocampal CREB-BDNF signaling in high fat, high fructose diet-fed rats
Jagan Kalivarathan,Kalpana Kalaivanan,Sathiya Priya Chandrasekaran,Dipti Nanda,Vidhya Ramachandran,Anuradha Carani Venkatraman
Journal of Functional Foods. 2020; 68: 103898
[Pubmed]  [Google Scholar] [DOI]
15 The protective effects of GLP-1 receptor agonist lixisenatide on oxygen-glucose deprivation/reperfusion (OGD/R)-induced deregulation of endothelial tube formation
Mochao Xiao,Daifeng Lu,Jiali Tian,Yang Yu,Qin Zhang,Lili Zhang,Dong Chang
RSC Advances. 2020; 10(17): 10245
[Pubmed]  [Google Scholar] [DOI]
16 Understanding the interplay between food structure, intestinal bacterial fermentation and appetite control
A. Dagbasi,A. M. Lett,K. Murphy,G. Frost
Proceedings of the Nutrition Society. 2020; : 1
[Pubmed]  [Google Scholar] [DOI]
17 Metronidazole-conjugates: A comprehensive review of recent developments towards synthesis and medicinal perspective
Om P.S. Patel,Omobolanle Janet Jesumoroti,Lesetja J. Legoabe,Richard M. Beteck
European Journal of Medicinal Chemistry. 2020; : 112994
[Pubmed]  [Google Scholar] [DOI]
18 Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: Narrative review and practical considerations for primary care providers
Angela Fitch,Amy Beth Ingersoll
Postgraduate Medicine. 2020;
[Pubmed]  [Google Scholar] [DOI]
19 Recombinant Fusion of Glucagon-Like Peptide-1 and an Albumin Binding Domain Provides Glycemic Control for a Week in Diabetic Mice
Parisa Yousefpour,Anastasia Varanko,Rishi Subrahmanyan,Ashutosh Chilkoti
Advanced Therapeutics. 2020; : 2000073
[Pubmed]  [Google Scholar] [DOI]
20 The methionine aminopeptidase 2 inhibitor, TNP-470, enhances the antidiabetic properties of sitagliptin in mice by upregulating xenin
Sarah L. Craig,Victor A. Gault,Peter R. Flatt,Nigel Irwin
Biochemical Pharmacology. 2020; : 114355
[Pubmed]  [Google Scholar] [DOI]
21 Encapsulation in Polymeric Nanoparticles Enhances the Enzymatic Stability and the Permeability of the GLP-1 Analog, Liraglutide, Across a Culture Model of Intestinal Permeability
Ruba Ismail,Alexandra Bocsik,Gábor Katona,Ilona Gróf,Mária A. Deli,Ildikó Csóka
Pharmaceutics. 2019; 11(11): 599
[Pubmed]  [Google Scholar] [DOI]
22 An overview on small molecule-induced differentiation of mesenchymal stem cells into beta cells for diabetic therapy
Nimshitha Pavathuparambil Abdul Manaph,Kisha N. Sivanathan,Jodie Nitschke,Xin-Fu Zhou,Patrick T. Coates,Christopher John Drogemuller
Stem Cell Research & Therapy. 2019; 10(1)
[Pubmed]  [Google Scholar] [DOI]
23 Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency
Seyed Ebrahim Alavi,Peter J. Cabot,Peter M. Moyle
Molecular Pharmaceutics. 2019;
[Pubmed]  [Google Scholar] [DOI]
24 The Effects of Exenatide Once Weekly (EXQW) and Exenatide Twice a Day (EXBID) on Beta-Cell Function in Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Jie Wang,Xinye Jin,Ping An,Songyan Yu,Yiming Mu
Journal of Diabetes Research. 2019; 2019: 1
[Pubmed]  [Google Scholar] [DOI]
25 Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People
Ajay Sood,Arthur Swislocki
Metabolic Syndrome and Related Disorders. 2019;
[Pubmed]  [Google Scholar] [DOI]
26 Design and synthesis of rhamnose-modified exenatide conjugate by sortase A-mediated ligation
Chen Li,Shijie Dai,Aijie Cao,Zhifang Zhou,Zhimeng Wu
Journal of Carbohydrate Chemistry. 2019; 38(3): 167
[Pubmed]  [Google Scholar] [DOI]
27 Lead Optimization Resources in Drug Discovery for Diabetes
Pragya Tiwari,Ashish Katyal,Mohd F. Khan,Ghulam Md. Ashraf,Khurshid Ahmad
Endocrine, Metabolic & Immune Disorders - Drug Targets. 2019; 19(6): 754
[Pubmed]  [Google Scholar] [DOI]
28 Novel pharmacotherapy for burn wounds: what are the advancements
Michael R. Hamblin
Expert Opinion on Pharmacotherapy. 2018; : 1
[Pubmed]  [Google Scholar] [DOI]
29 A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes
Irene Romera,Ana Cebrián-Cuenca,Fernando Álvarez-Guisasola,Fernando Gomez-Peralta,Jesús Reviriego
Diabetes Therapy. 2018;
[Pubmed]  [Google Scholar] [DOI]
30 Novel insights into the dynamics behavior of glucagon-like peptide-1 receptor with its small molecule agonists
Khyati Girdhar,Budheswar Dehury,Mahender Kumar Singh,Vineeth P. Daniel,Abhinav Choubey,Surbhi Dogra,Sunil Kumar,Prosenjit Mondal
Journal of Biomolecular Structure and Dynamics. 2018; : 1
[Pubmed]  [Google Scholar] [DOI]
31 GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
Andrei C. Sposito,Otávio Berwanger,Luiz Sérgio F. de Carvalho,José Francisco Kerr Saraiva
Cardiovascular Diabetology. 2018; 17(1)
[Pubmed]  [Google Scholar] [DOI]
32 Evaluation of Drug Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors Based on Target Molecular Binding Occupancy
Risa Takayanagi,Takumi Uchida,Koji Kimura,Yasuhiko Yamada
Biological and Pharmaceutical Bulletin. 2018; 41(2): 153
[Pubmed]  [Google Scholar] [DOI]
33 A capillary zone electrophoresis method to investigate the oligomerization of the human Islet Amyloid Polypeptide involved in Type 2 Diabetes
Corentin Berardet,Julia Kaffy,Sandrine Ongeri,Myriam Taverna
Journal of Chromatography A. 2018;
[Pubmed]  [Google Scholar] [DOI]
34 Novel technique of insulin loading into porous carriers for oral delivery
Sarah Y. Eilleia,Mahmoud E. Soliman,Samar Mansour,Ahmed. S. Geneidi
Asian Journal of Pharmaceutical Sciences. 2018;
[Pubmed]  [Google Scholar] [DOI]
35 Antidiabetic therapies and male reproductive function: where do we stand?
R S Tavares,S Escada-Rebelo,A F Silva,M I Sousa,J Ramalho-Santos,S Amaral
Reproduction. 2018; 155(1): R13
[Pubmed]  [Google Scholar] [DOI]
36 Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide
Angélique Gajahi Soudahome,Aurélie Catan,Pierre Giraud,Sandrine Assouan Kouao,Alexis Guerin-Dubourg,Xavier Debussche,Nathalie Le Moullec,Emmanuel Bourdon,Susana B. Bravo,Beatriz Paradela-Dobarro,Ezequiel Álvarez,Olivier Meilhac,Philippe Rondeau,Joël Couprie
Journal of Biological Chemistry. 2018; 293(13): 4778
[Pubmed]  [Google Scholar] [DOI]
37 Peptibodies: An elegant solution for a long-standing problem
Marco Cavaco,Miguel A. R. B. Castanho,Vera Neves
Biopolymers. 2017; : e23095
[Pubmed]  [Google Scholar] [DOI]
38 Discovery of a Novel Series of Orally Bioavailable and CNS Penetrant Glucagon-like Peptide-1 Receptor (GLP-1R) Noncompetitive Antagonists Based on a 1,3-Disubstituted-7-aryl-5,5-bis(trifluoromethyl)-5,8-dihydropyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione Core
Kellie D. Nance,Emily L. Days,C. David Weaver,Anastasia Coldren,Tiffany D. Farmer,Hyekyung P. Cho,Colleen M. Niswender,Anna L. Blobaum,Kevin D. Niswender,Craig W. Lindsley
Journal of Medicinal Chemistry. 2017;
[Pubmed]  [Google Scholar] [DOI]
39 Gold nanoparticles as an efficient drug delivery system for GLP-1 peptides
Magdalena Pérez-Ortiz,Claudio Zapata-Urzúa,Gerardo A. Acosta,Alejandro Álvarez-Lueje,Fernando Albericio,Marcelo J. Kogan
Colloids and Surfaces B: Biointerfaces. 2017; 158: 25
[Pubmed]  [Google Scholar] [DOI]
40 Lixisenatide as add-on treatment among patients with different ß-cell function levels as assessed by HOMA-ß index
Riccardo C. Bonadonna,Lawrence Blonde,Mikhail Antsiferov,Rachele Berria,Pierre Gourdy,Mensud Hatunic,Viswanathan Mohan,Michael Horowitz
Diabetes/Metabolism Research and Reviews. 2017; : e2897
[Pubmed]  [Google Scholar] [DOI]
41 Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
Seungah Lee,Dong Yun Lee
Annals of Pediatric Endocrinology & Metabolism. 2017; 22(1): 15
[Pubmed]  [Google Scholar] [DOI]
42 The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy
Jerry Meece
Advances in Therapy. 2017;
[Pubmed]  [Google Scholar] [DOI]
43 Liraglutide protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury through the suppression of the SR-Ca2+–XO–ROS axis via activation of the GLP-1R/PI3K/Akt/survivin pathways
Ying Zhang,Hao Zhou,Wenbo Wu,Chen Shi,Shunying Hu,Tong Yin,Qiang Ma,Tianwen Han,Yingqian Zhang,Feng Tian,Yundai Chen
Free Radical Biology and Medicine. 2016; 95: 278
[Pubmed]  [Google Scholar] [DOI]
44 Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation
Harika Meduru,Yeng-Tseng Wang,Jeffrey Tsai,Yu-Ching Chen
International Journal of Molecular Sciences. 2016; 17(6): 920
[Pubmed]  [Google Scholar] [DOI]
45 Albiglutide: a unique GLP-1 receptor agonist
Marc S. Rendell
Expert Opinion on Biological Therapy. 2016; 16(12): 1557
[Pubmed]  [Google Scholar] [DOI]
46 Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus
Markolf Hanefeld,Denis Raccah,Louis Monnier
Expert Opinion on Drug Metabolism & Toxicology. 2016; : 1
[Pubmed]  [Google Scholar] [DOI]
47 Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions
Amit Lakhanpal,Ernest Brahn
Clinical Rheumatology. 2016; 35(12): 2869
[Pubmed]  [Google Scholar] [DOI]
48 Quelle place pour les nouveaux antidiabétiques dans la prise en charge du diabète du sujet âgé ?
J.-F. Blicklé
Médecine des Maladies Métaboliques. 2016; 10(6): 574
[Pubmed]  [Google Scholar] [DOI]
49 Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice
L M McShane,N Irwin,D O’Flynn,Z J Franklin,C M Hewage,F P M O’Harte
Journal of Endocrinology. 2016; 229(3): 319
[Pubmed]  [Google Scholar] [DOI]
50 A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
Sheena Kayaniyil,Greta Lozano-Ortega,Heather A. Bennett,Kristina Johnsson,Alka Shaunik,Susan Grandy,Bernt Kartman
Diabetes Therapy. 2016;
[Pubmed]  [Google Scholar] [DOI]
51 Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study
Ali A Rizvi,Angelo Maria Patti,Rosaria Vincenza Giglio,Dragana Nikolic,Antonella Amato,Noor Al-Busaidi,Khalid Al-Rasadi,Maurizio Soresi,Maciej Banach,Giuseppe Montalto,Manfredi Rizzo
Expert Opinion on Biological Therapy. 2015; 15(10): 1391
[Pubmed]  [Google Scholar] [DOI]
52 Synthesis and Evaluation of a Series of Long-Acting Glucagon-Like Peptide-1 (GLP-1) Pentasaccharide Conjugates for the Treatment of Type 2 Diabetes
Nigel Irwin,Steven Patterson,Martin de Kort,R. Charlotte Moffett,Jeffry A. J. Wisse,Wim H. A. Dokter,Ebo S. Bos,André M. M. Miltenburg,Peter R. Flatt
ChemMedChem. 2015; 10(8): 1424
[Pubmed]  [Google Scholar] [DOI]
53 Incretin-based therapies for obesity treatment
Aline Haas de Mello,Morgana Prá,Larissa Colonetti Cardoso,Rosiane de Bona Schraiber,Gislaine Tezza Rezin
Metabolism. 2015; 64(9): 967
[Pubmed]  [Google Scholar] [DOI]
54 Enhanced survival of human mesenchymal stem cells following co-delivery with glucagon-like peptide-1 analogue in fibrin gel
Hyerim Jin,Woo Jung Lee,Soongdong Lee,TacGhee Yi,Sun Uk Song,Gayong Shim,Yu-Kyoung Oh
Journal of Pharmaceutical Investigation. 2014;
[Pubmed]  [Google Scholar] [DOI]
55 Pharmacokinetic study of HS061, a new human insulin, in non-diabetic rat using ultra performance liquid chromatography–tandem mass spectrometry
Xiaoyan Zhu,Jingjing Liu,Jie Wu,Rongyue Cao,Taiming Li
Journal of Chromatography B. 2014; 967: 50
[Pubmed]  [Google Scholar] [DOI]


Read this article